PDCD1 and non-small cell lung carcinoma: In a study of 559 NSCLC patients receiving anti-PD1 immunotherapy, patients experiencing multiple-site irAEs had significantly longer PFS than those with single-site irAEs; however, OS was no longer increased in the multivariate analysis [25].